Adenocarcinoma of the appendix is a cancer that starts from the gland-forming cells lining the inside of the appendix. The appendix is a small pouch attached to the first part of the large bowel. This type of cancer forms glands that look much like those of colon cancer, so it is also called colonic-type, intestinal-type, or non-mucinous adenocarcinoma. Your pathology report will usually say “adenocarcinoma.”
This article explains how adenocarcinoma of the appendix differs from other appendix cancers and how it is graded and staged. It also explains what the margins, lymph nodes, and other findings in your pathology report mean.
Several different cancers can start in the appendix, and each one is described differently in a pathology report. When a report says only “adenocarcinoma,” it means a gland-forming cancer that does not fit one of the more specific types below.
Adenocarcinoma accounts for about one in four cancers of the appendix. It behaves more like colon cancer than the other types, and it is less likely than mucinous adenocarcinoma to have spread inside the abdomen when it is found.
Adenocarcinoma of the appendix is uncommon. Most people are diagnosed in their 50s or 60s. Like other appendix cancers, it has become more common over the past few decades, including in people under 50.
The cause of adenocarcinoma of the appendix is not known in most people. It is thought to develop in the same way as most colon cancers. First, a noncancerous growth called an adenoma or a serrated lesion forms in the appendix lining. Over time, the cells in that growth can acquire more genetic changes and become cancer.
The genes most often changed include KRAS and TP53. KRAS signals cells to keep dividing, while TP53 normally stops damaged cells from dividing. Rarely, the cancer is linked to an inherited condition called Lynch syndrome. This is described in the biomarker section below.
Adenocarcinoma of the appendix often causes the same symptoms as acute appendicitis, such as pain in the lower right abdomen, fever, and nausea. The tumor causes these symptoms by blocking the appendix. Many cancers are therefore found unexpectedly after the appendix has been removed.
Other people notice a mass in the lower right abdomen, a change in bowel habits, or weight loss. When the cancer has spread, symptoms may include swelling of the abdomen or pain under the right ribs. Some cancers are found during a colonoscopy or a scan done for another reason.
The diagnosis of adenocarcinoma of the appendix is usually made after the appendix is removed in a surgery called an appendectomy. Sometimes it is made on a biopsy taken during a colonoscopy, or after a larger operation called a right hemicolectomy. A pathologist examines the tissue under the microscope.
Under the microscope, the cancer cells form irregular glands that invade the appendix wall. The pathologist often finds an adenoma or serrated lesion in the lining next to the cancer. This finding helps confirm that the cancer started in the appendix.
A tumor at the base of the appendix may have started in the appendix or in the cecum, the first part of the large bowel. The pathologist must decide which. Cancers starting in the cecum are staged and reported as colon cancer. Stains such as CK20 and CDX2 confirm that the cancer is of bowel origin but cannot separate the appendix from the colon.
Once the diagnosis is made, a CT scan of the chest, abdomen, and pelvis is used to look for spread. A colonoscopy is also usually performed to check the rest of the large bowel. Blood tests for tumor markers, such as CEA, are often ordered.
The grade of adenocarcinoma of the appendix describes how much the cancer cells still form glands. Tumors that form more glands look more like normal tissue. Grade helps predict how the cancer will behave and guides treatment decisions.
The College of American Pathologists (CAP) appendix protocol, version 5.1.0.0 (2022), uses three grades:
Adenocarcinoma of the appendix starts in the inner lining and grows outward through the wall. It can reach the submucosa, muscularis propria, and subserosa, and is covered on the outside by the serosa. The report also says whether the cancer has reached the mesoappendix, which is the fatty tissue holding the appendix and its blood vessels.
The deepest layer the cancer reaches determines the tumor stage (pT). Cancer that breaks through the serosa can spread to the lining of the abdomen, called the peritoneum.
Perineural invasion means adenocarcinoma cells were found growing along or around a nerve in or near the appendix. Cancer that follows nerves can reach tissue beyond the main tumor. Your report will state whether perineural invasion was “not identified,” “present,” or “cannot be determined” for the tissue examined.
Lymphovascular invasion means adenocarcinoma cells were found inside a small blood vessel or lymphatic channel. Cancer cells in these channels can reach the lymph nodes, liver, or other organs. The report will state whether it was “not identified,” “present,” or “cannot be determined” for the tissue examined. Lymphovascular invasion is one of the features used to decide whether a right hemicolectomy is needed after an appendectomy.
A margin is an edge of tissue cut by the surgeon to remove the adenocarcinoma. In an appendectomy, the proximal margin is where the appendix was divided from the large bowel. The mesenteric margin is the cut edge of the mesoappendix. In a right hemicolectomy, the cut ends of the small and large bowel are also examined.
Following the CAP appendix protocol, version 5.1.0.0 (2022), margins are reported as negative or positive, with no “close” category:
Lymph nodes are small immune organs that filter fluid draining from tissues. Adenocarcinoma of the appendix spreads to lymph nodes more often than most other appendix cancers. In a large United States study, about 1 in 4 people with this cancer had lymph node spread.
An appendectomy removes few or no lymph nodes, so a right hemicolectomy is usually needed to examine them. Surgeons usually examine at least 12 lymph nodes. The report gives the number examined and the number containing cancer. Some reports describe tumor deposits, meaning separate cancer nodules in the surrounding fat without lymph node tissue. It may also note extranodal extension, meaning cancer has grown through the outer capsule of a lymph node.
Tumors that are confined to the submucosa (pT1), well or moderately differentiated, and without lymphovascular invasion rarely spread to lymph nodes. In the same study, fewer than 2 in 100 of these low-risk tumors spread to lymph nodes.
Biomarker testing for adenocarcinoma of the appendix is similar to testing for colon cancer. It is most often performed when the cancer has spread or returned, to look for features that may open specific treatment options.
Mismatch repair proteins fix errors that occur when a cell copies its DNA. Testing looks at four proteins: MLH1, PMS2, MSH2, and MSH6. Testing uses immunohistochemistry for the proteins or a DNA test for microsatellite instability. Fewer than 2 in 100 appendix cancers are mismatch repair deficient.
KRAS, NRAS, and BRAF are genes that control cell growth signals. They are usually tested together by DNA sequencing, often as part of a larger next-generation sequencing panel.
Tumor mutational burden is the number of gene changes in the cancer, measured in mutations per megabase (mut/Mb) by next-generation sequencing.
The Biomarkers and Genetic Testing section explains these tests in more detail, including our articles on KRAS, NRAS, and BRAF in colorectal cancer.
The American Joint Committee on Cancer (AJCC) system for appendix carcinomas, Version 9 (2023), is used to stage adenocarcinoma of the appendix. The pathologist assigns the tumor stage (pT) and nodal stage (pN), and imaging usually assesses distant spread. See our article on TNM staging to learn how the stage groups are formed.
Distant spread to the lining of the abdomen is M1b, and spread beyond it, such as to the liver or lungs, is M1c. For M1b disease, a grade 1 cancer is stage IVA, while a grade 2 or grade 3 cancer is stage IVB.
The prognosis for adenocarcinoma of the appendix depends mainly on the stage. In a Japanese multicenter study, about 91% of people with stage 0 or I disease were alive after 5 years. The figure was about 69% for stage II or III and about 7% for stage IV. In other words, about 93% of people with stage IV disease were not alive at 5 years. In a United States referral-center series, 3-year survival was 87% for stage I to II, 55% for stage III, and 36% for stage IV.
Once the cancer has spread to distant sites, adenocarcinoma of the appendix generally has a less favorable outlook than mucinous adenocarcinoma. The findings linked to a worse outlook are:
After adenocarcinoma of the appendix is confirmed, the next steps depend on the stage, grade, margins, and lymph node results. Treatment is usually similar to that for colon cancer. A team that includes a surgeon and a medical oncologist plans care. The NCCN released a dedicated appendix cancer guideline for the first time in 2025.
If testing suggests Lynch syndrome, genetic counseling can help you and your family members understand their risk.